α-Brom-α-jodtoluol

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: α-Brom-α-jodtoluol
• 英文别名: Iodobenzyl bromide；[bromo(iodo)methyl]benzene
• 化学式: C₇H₆BrI
• 分子量: 296.933
• InChiKey: OHRZXIJYFUZSJQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为产物：
  描述：

  α,α-二溴甲苯 在 反式-双(三苯基膦)合氯化羰基铑(Ⅰ) 作用下， 反应 2.5h， 生成 α-Brom-α-jodtoluol
  参考文献：
  名称：

  VIII族金属络合物作为烷基卤化物之间卤素交换的催化剂

  摘要：

  几个共同ordinatively不饱和d 6和d 8组VIII金属络合物可用于多种烷基卤化物之间卤素交换反应有效的催化剂。

  DOI：

  10.1039/c39750000418

文献信息

• [EN] COMPOUNDS AND METHODS FOR TARGETING HSP90<br/>[FR] COMPOSÉS ET PROCÉDÉS DE CIBLAGE DE HSP90
  申请人：UNIV DUKE

  公开号：WO2017184956A1

  公开（公告）日：2017-10-26

  Described herein are compounds that may selectively bind to Hsp90, methods of using the compounds, and kits including the compounds. The compounds may allow for selective detection of Hsp90 in a sample.

  本发明描述了可能选择性地与Hsp90结合的化合物，使用这些化合物的方法，以及包括这些化合物的试剂盒。这些化合物可能允许在样本中选择性地检测Hsp90。
• AGENT FOR TREATMENT OF DIABETES
  申请人：Dainippon Sumitomo Pharma Co., Ltd.

  公开号：EP2351563A1

  公开（公告）日：2011-08-03

  The present invention provides a hypoglycemic agent useful for treating diabetes or other similar diseases which has no adverse effects. Furthermore, the present invention provides a hypoglycemic agent comprising a combination of an antidiabetic drug and 2-methyl-2-[(4-(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]prop-1-en-1-yl}benzyl)oxy]propanoic acid or a pharmaceutically acceptable salt thereof.

  本发明提供了一种降血糖药物，可用于治疗糖尿病或其他类似疾病，并且没有不良影响。此外，本发明提供了一种降血糖药物，包括抗糖尿病药物和2-甲基-2-[(4-(1E)-3-[2-(4-甲基苯甲酰基)-1H-吡咯-1-基]丙-1-烯-1-基}苯甲氧基)丙酸或其药学上可接受的盐的组合。
• DEVICES FOR HIGH-FREQUENCY TECHNOLOGY, LIQUID-CRYSTALLINE MEDIA AND COMPOUNDS
  申请人：Manabe Atsutaka

  公开号：US20120261615A1

  公开（公告）日：2012-10-18

  The present invention relates to a device for high-frequency technology, or for the microwave region and millimetre wave region of the electromagnetic spectrum, characterised in that it contains a liquid-crystal medium which consists of one or more compounds, which one or more compounds, which contain 6 to 15 five-, six- or seven-membered rings, preferably 1,4-linked phenylene rings, or in that it contains a liquid-crystal medium which itself comprises a component A, which itself consists of one or more of the said compounds, which one or more compounds, which contain 6 to 15 five-, six- or seven-membered rings, preferably 1,4-linked phenylene rings. The present invention additionally relates to compounds of the formula (I), in which the parameters have the meanings given in the text, and to the corresponding, novel liquid-crystal media, to the use and preparation thereof, and to the production and use of the devices. The devices according to the invention are particularly suitable phase shifters in the microwave and millimetre wave region, for microwave and millimetre wave array antennas and very particularly for so-called tunable “reflectarrays”.

  本发明涉及一种高频技术或电磁波谱的微波区和毫米波区的装置，其特征在于它包含一种液晶介质，该液晶介质由一个或多个化合物组成，该一个或多个化合物包含6至15个五元、六元或七元环，优选为1,4-联苯环，或者它包含一种液晶介质，该液晶介质本身包括组分A，该组分A由一个或多个上述化合物组成，该一个或多个化合物包含6至15个五元、六元或七元环，优选为1,4-联苯环。本发明还涉及公式（I）中的化合物，其中参数具有本文中给出的含义，以及相应的新型液晶介质，它们的使用和制备，以及装置的生产和使用。本发明的装置特别适用于微波和毫米波区的相移器，用于微波和毫米波阵列天线，特别是用于所谓的可调“反射阵列”。
• Compositions and methods for treating cancer
  申请人：Tidmarsh George

  公开号：US20060142207A1

  公开（公告）日：2006-06-29

  Methods and compositions are provided for the treatment of cancer that take advantage of the increased uptake of glucose-anti-neoplastic agent conjugates in cancer cells relative to normal cells.

  本发明提供了一种治疗癌症的方法和组合物，利用了癌细胞相对于正常细胞对葡萄糖-抗肿瘤药物结合物的摄取增加的特性。
• Novel heteroaryl derivative
  申请人：Watanabe Ken-ichi

  公开号：US20060194857A1

  公开（公告）日：2006-08-31

  A heteroaryl derivative of the formula (1): (wherein Ring Z is an optionally substituted heteroaryl, R 1 is a carboxyl group or an alkoxycarbonyl group, etc., W 1 and W 2 are an optionally substituted lower alkylene, Ar 1 is an optionally substituted arylene or an optionally substituted heteroarylene, W 3 is a single bond, a lower alkylene, a lower alkenylene, etc., W 4 is a single bond, —NR 10 —, etc., Ar 2 is an optionally substituted aryl or an optionally substituted heteroaryl), or a prodrug thereof, or a pharmaceutically acceptable salt thereof.

  式（1）中，环Z是一种可选的取代杂环基，R1是羧基或烷氧羰基基团等，W1和W2是可选的取代的低碳基链，Ar1是可选的取代芳基或可选的取代杂芳基，W3是单键，低碳基链，低烯基链等，W4是单键，—NR10—等，Ar2是可选的取代芳基或可选的取代杂芳基的杂环基，或其前体药物，或其药物可接受的盐。